{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:27:23Z","timestamp":1699403243798},"reference-count":0,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T00:00:00Z","timestamp":1451865600000},"content-version":"vor","delay-in-days":15649,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[1973,3]]},"abstract":"<jats:p>The effect of a single oral dose of tripelennamine, 100 mg., methyldopa, 500 mg., d\u2010amphetamine, 10 mg., amitriptyline, 50 mg., or prochlorperazine, 25 mg., on the blood pressures of hypertensive patients treated chronically with guanethidine was measured half\u2010hourly for 8 hours. D\u2010amphetamine antagonized the antihypertensive effect of guanethidine in the lying systolic blood pressure, while the orthostatic hypotension persisted. The effect of d\u2010amphetamine seems to be due to the direct stimulation of vasoconstrictor receptors. Tripelennamine, amitriptyline and prochlorperazine had no demonstrable short\u2010term effect on the guanethidine action. Methyldopa potentiated guanethidine in the standing diastolic blood pressure.<\/jats:p>","DOI":"10.1002\/cpt1973142190","type":"journal-article","created":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T01:20:33Z","timestamp":1451956833000},"page":"190-195","source":"Crossref","is-referenced-by-count":7,"title":["Drug interactions with guanethidine"],"prefix":"10.1111","volume":"14","author":[{"given":"Karl F.","family":"Ober","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard I. H.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,1,4]]},"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt1973142190","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt1973142190","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt1973142190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:34:04Z","timestamp":1699364044000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt1973142190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1973,3]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1973,3]]}},"alternative-id":["10.1002\/cpt1973142190"],"URL":"https:\/\/doi.org\/10.1002\/cpt1973142190","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[1973,3]]}}}